Results 161 to 170 of about 49,554 (304)

The expression and biological function of chemokine CXCL12 and receptor CXCR4/CXCR7 in placenta accreta spectrum disorders. [PDF]

J Cell Mol Med, 2020
Long Y, Jiang Y, Zeng J, Dang Y, Chen Y, Lin J, Wei H, Xia H, Long J, Luo C, Chen Z, Huang Y, Li M.   +12 more
europepmc   +1 more source

Expression of Chemokine CXCL12 and Its Receptor CXCR4 in Folliculostellate (FS) Cells of the Rat Anterior Pituitary Gland: The CXCL12/CXCR4 Axis Induces Interconnection of FS Cells [PDF]

, 2012
Kotaro Horiguchi, Cimi Ilmiawati, Ken Fujiwara, Takehiro Tsukada, Motoshi Kikuchi, Takashi Yashiro   +5 more
openalex   +1 more source

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source

Characterization and Mathematical Modeling of Alginate/Chitosan-Based Nanoparticles Releasing the Chemokine CXCL12 to Attract Glioblastoma Cells. [PDF]

Pharmaceutics, 2020
Gascon S, Giraldo Solano A, El Kheir W, Therriault H, Berthelin P, Cattier B, Marcos B, Virgilio N, Paquette B, Faucheux N, Lauzon MA.   +10 more
europepmc   +1 more source

Activating and Inhibitory Ly49 Receptors Modulate NK Cell Chemotaxis to CXC Chemokine Ligand (CXCL) 10 and CXCL12 [PDF]

, 2003
Marit Inngjerdingen, Bent Rolstad, James C. Ryan   +2 more
openalex   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Serum CXCL10, CXCL11, CXCL12 and CXCL14 chemokine patterns in patients with acute liver injury [PDF]

, 2018
Arnaud Chalin, B. Lefevre, Christelle Devisme, Virginie Carrière, Laurence Amiot, Michel Samson   +5 more
openalex   +1 more source

MEK1/2 inhibitor inhibits neointima formation by activating miR-126-3p/ C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 4 (CXCR4) axis

, 2022
Yali Yan, Mengmeng Zhu, Jialing Ma, Xiaoyu He, Xiaoxiao Yang, Hongmei Xu, Meixiu Jiang, Shuang Zhang, Yajun Duan, Jihong Han, Yuanli Chen   +10 more
openalex   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

[IL-17A activates mouse lung fibroblasts through promoting chemokine CXCL12 secretion]. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban, 2020
Wang H, Lyu J, Chen L, Yu W.
europepmc   +1 more source